These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15212304)

  • 1. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
    Masubuchi N
    Pharmazie; 2004 May; 59(5):374-7. PubMed ID: 15212304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
    Oguma T; Morikawa H; Iwasaki D; Atsumi R
    Biomed Chromatogr; 2005 Jan; 19(1):19-26. PubMed ID: 15484225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
    Shiose Y; Kuga H; Yamashita F; Hashida M
    J Pharm Biomed Anal; 2007 Mar; 43(4):1290-6. PubMed ID: 17127025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
    Ochi Y; Shiose Y; Kuga H; Kumazawa E
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):323-332. PubMed ID: 15517271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
    Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
    Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
    Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
    Wente MN; Kleeff J; Büchler MW; Wanders J; Cheverton P; Langman S; Friess H
    Invest New Drugs; 2005 Aug; 23(4):339-47. PubMed ID: 16012793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
    Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
    Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Kumazawa E; Jimbo T; Ochi Y; Tohgo A
    Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models.
    Kumazawa E; Ochi Y
    Cancer Sci; 2004 Feb; 95(2):168-75. PubMed ID: 14965368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
    Frapolli R; Zucchetti M; Sessa C; Marsoni S; Viganò L; Locatelli A; Rulli E; Compagnoni A; Bello E; Pisano C; Carminati P; D'Incalci M
    Eur J Cancer; 2010 Feb; 46(3):505-16. PubMed ID: 20007015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
    Oguma T; Cicci D; Gaudette F; Gauthier-Dubois G; Guilbaud R; Atsumi R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):249-56. PubMed ID: 15734166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
    Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
    Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
    Shiose Y; Ochi Y; Kuga H; Yamashita F; Hashida M
    Biol Pharm Bull; 2007 Dec; 30(12):2365-70. PubMed ID: 18057727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.